PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 93 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,401,320 | -57.0% | 143,964 | -28.8% | 0.00% | -57.1% |
| Q2 2023 | $5,587,802 | +2.2% | 202,310 | -14.9% | 0.01% | -12.5% |
| Q1 2023 | $5,465,352 | +450.3% | 237,624 | +161.1% | 0.01% | +300.0% |
| Q4 2022 | $993,083 | -100.0% | 91,025 | -61.5% | 0.00% | -33.3% |
| Q3 2022 | $1,991,697,000 | +477.0% | 236,263 | +441.4% | 0.00% | +200.0% |
| Q2 2022 | $345,169,000 | -23.9% | 43,637 | +127.9% | 0.00% | 0.0% |
| Q1 2022 | $453,425,000 | -65.7% | 19,148 | -50.5% | 0.00% | -50.0% |
| Q4 2021 | $1,322,104,000 | +831.8% | 38,658 | +382.8% | 0.00% | – |
| Q3 2021 | $141,884,000 | +97.5% | 8,007 | +400.1% | 0.00% | – |
| Q2 2021 | $71,853,000 | -40.2% | 1,601 | -65.5% | 0.00% | – |
| Q1 2021 | $120,124,000 | -18.9% | 4,638 | -36.9% | 0.00% | – |
| Q4 2020 | $148,075,000 | +6.6% | 7,345 | +3.4% | 0.00% | – |
| Q3 2020 | $138,922,000 | +819.0% | 7,106 | +730.1% | 0.00% | – |
| Q2 2020 | $15,117,000 | -61.0% | 856 | -84.4% | 0.00% | – |
| Q1 2020 | $38,731,000 | +163.0% | 5,486 | +162.6% | 0.00% | – |
| Q4 2019 | $14,727,000 | -36.0% | 2,089 | +9.0% | 0.00% | – |
| Q3 2019 | $23,011,000 | +546.4% | 1,916 | +551.7% | 0.00% | – |
| Q2 2019 | $3,560,000 | +7020.0% | 294 | +7250.0% | 0.00% | – |
| Q1 2019 | $50,000 | -98.4% | 4 | -99.1% | 0.00% | – |
| Q4 2018 | $3,143,000 | -30.6% | 467 | +6.1% | 0.00% | – |
| Q3 2018 | $4,528,000 | +53.1% | 440 | 0.0% | 0.00% | – |
| Q2 2018 | $2,957,000 | -86.8% | 440 | -83.1% | 0.00% | – |
| Q1 2018 | $22,360,000 | -62.3% | 2,603 | -8.6% | 0.00% | – |
| Q4 2017 | $59,238,000 | +409.5% | 2,848 | +332.8% | 0.00% | – |
| Q3 2017 | $11,627,000 | +42.2% | 658 | -9.0% | 0.00% | – |
| Q2 2017 | $8,177,000 | +2939.8% | 723 | +3342.9% | 0.00% | – |
| Q1 2017 | $269,000 | -96.6% | 21 | -94.2% | 0.00% | – |
| Q4 2016 | $7,982,000 | +39.4% | 363 | +33.9% | 0.00% | – |
| Q3 2016 | $5,726,000 | – | 271 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |